These observations highlight the persistent limitations in current management strategies for severe EGFR-TKI-related pneumonitis, including uncertainties regarding optimal corticosteroid dosing, timing of initiation, and the potential benefit of adjunctive therapeutic agents. This evidence concerns the gene EGFR and pneumonitis.